Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study

Vaccine

Volumn 32, Issue 50, 2014, Pages 6838-6846

  Leroux Roels, Geert ^a   Maes, Cathy ^a   De Boever, Fien ^a   Traskine, Magali ^b   Rüggeberg, Jens U ^b   Borys, Dorota ^b  

^a GHENT UNIVERSITY   (Belgium)

^b GSK   (Belgium)

Author keywords

DPly; PhtD; Pneumococcal protein containing vaccine; Pneumolysin; Streptococcus pneumoniae

Indexed keywords

ANTIBODY; FRAGILE HISTIDINE TRIAD PROTEIN; HISTIDINE TRIAD PROTEIN D VACCINE; PLACEBO; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; PNEUMOLYSIN TOXOID VACCINE; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; HISTIDINE TRIAD PROTEIN; HYDROLASE; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; STREPTOLYSIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; APHTHOUS STOMATITIS; ARTICLE; BACTERIAL IMMUNITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFECTION; HAND EDEMA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MUSCULOSKELETAL INJURY; MYALGIA; NONTYPEABLE HAEMOPHILUS INFLUENZAE; NORMAL HUMAN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN CONTENT; RANDOMIZED CONTROLLED TRIAL; REACTOGENICITY; SEROTYPE; SINGLE DRUG DOSE; SKIN REDNESS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; PATHOLOGY; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; HYDROLASES; MALE; PLACEBOS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; VACCINATION; YOUNG ADULT;

EID: 84909636565     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.052     Document Type: Article

References (34)

1. Lynch J.P., Zhanel G.G. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010, 16(3):217-225.
2. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
3. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369(9568):1179-1186.
4. Crisinel P.A., Chevalier I., Rallu F., Tapiero B., Lamarre V., Thibault R., et al. Invasive pneumococcal disease after implementation of a reduced three-dose pneumococcal conjugate vaccine program: a pediatric tertiary care center experience. Eur J Pediatr 2010, 169(11):1311-1315.
5. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
6. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378:1962-1973. 9807.
7. Musher D.M., Phan H.M., Baughn R.E. Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J Infect Dis 2001, 183(5):827-830.
8. Alexander J.E., Lock R.A., Peeters C.C., Poolman J.T., Andrew P.W., Mitchell T.J., et al. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 1994, 62(12):5683-5688.
9. Ogunniyi A.D., Woodrow M.C., Poolman J.T., Paton J.C. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun 2001, 69(10):5997-6003.
10. Garcia-Suarez M.M., Cima-Cabal M.D., Florez N., Garcia P., Cernuda-Cernuda R., Astudillo A., et al. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect Immun 2004, 72(8):4534-4540.
11. Denoel P., Philipp M.T., Doyle L., Martin D., Carletti G., Poolman J.T. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 2011, 29(33):5495-5501.
12. Hamel J., Charland N., Pineau I., Ouellet C., Rioux S., Martin D., et al. Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun 2004, 72(5):2659-2670.
13. Hava D.L., Camilli A. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol Microbiol 2002, 45(5):1389-1406.
14. Adamou J.E., Heinrichs J.H., Erwin A.L., Walsh W., Gayle T., Dormitzer M., et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 2001, 69(2):949-958.
15. Godfroid F., Hermand P., Verlant V., Denoel P., Poolman J.T. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 2011, 79(1):238-245.
16. Khan M.N., Pichichero M.E. Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humans. Vaccine 2012, 30(18):2900-2907.
17. Leroux-Roels I., Devaster J.M., Leroux-Roels G., Verlant V., Henckaerts I., Moris P., et al. Adjuvant system AS02 enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials. Vaccine 2013, pii: S0264-410X(13)01430-8. 10.1016/j.vaccine.2013.10.052.
18. Prymula R., Schuerman L. 10-Valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009, 8(11):1479-1500.
19. Findlay J.W., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 2000, 21(6):1249-1273.
20. Henckaerts I., Durant N., De G.D., Schuerman L., Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007, 25(13):2518-2527.
21. Kretsinger K., Broder K.R., Cortese M.M., Joyce M.P., Ortega-Sanchez I., Lee G.M., et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006, 55(RR-17):1-37.
22. Galazka A.M., Robertson S.E. Immunization against diphtheria with special emphasis on immunization of adults. Vaccine 1996, 14(9):845-857.
23. Kamtchoua T., Bologa M., Hopfer R., Neveu D., Hu B., Sheng X., et al. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine 2013, 31(2):327-333.
24. Seiberling M., Bologa M., Brookes R., Ochs M., Go K., Neveu D., et al. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults. Vaccine 2012, 30(52):7455-7460.
25. Bologa M., Kamtchoua T., Hopfer R., Sheng X., Hicks B., Bixler G., et al. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine. Vaccine 2012, 30(52):7461-7468.
26. Pichichero M.E., Kaur R., Casey J.R., Xu Q., Almudevar A., Ochs M. Antibody response to Streptococcus pneumoniae proteins PhtD, LytB, PcpA, PhtE and Ply after nasopharyngeal colonization and acute otitis media in children. Hum Vaccin Immunother 2012, 8(6):799-805.
27. Sharma S.K., Roumanes D., Almudevar A., Mosmann T.R., Pichichero M.E. CD4 T-cell responses among adults and young children in response to Streptococcus pneumoniae and Haemophilus influenzae vaccine candidate protein antigens. Vaccine 2013, 31(30):3090-3097.
28. Rapola S., Jantti V., Haikala R., Syrjanen R., Carlone G.M., Sampson J.S., et al. Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 2000, 182(4):1146-1152.
29. Holmlund E., Quiambao B., Ollgren J., Nohynek H., Kayhty H. Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage. Vaccine 2006, 24(1):57-65.
30. Holmlund E., Quiambao B., Ollgren J., Jaakkola T., Neyt C., Poolman J., et al. Antibodies to pneumococcal proteins PhtD, CbpA, and LytC in Filipino pregnant women and their infants in relation to pneumococcal carriage. Clin Vaccine Immunol 2009, 16(6):916-923.
31. Kaur R., Casey J.R., Pichichero M.E. Serum antibody response to five Streptococcus pneumoniae proteins during acute otitis media in otitis-prone and non-otitis-prone children. Pediatr Infect Dis J 2011, 30(8):645-650.
32. Huo Z., Spencer O., Miles J., Johnson J., Holliman R., Sheldon J., et al. Antibody response to pneumolysin and to pneumococcal capsular polysaccharide in healthy individuals and Streptococcus pneumoniae infected patients. Vaccine 2004, 22(9-10):1157-1161.
33. Francis J.P., Richmond P.C., Pomat W.S., Michael A., Keno H., Phuanukoonnon S., et al. Maternal antibodies to pneumolysin but not to pneumococcal surface protein A delay early pneumococcal carriage in high-risk Papua New Guinean infants. Clin Vaccine Immunol 2009, 16(11):1633-1638.
34. Guidance for Industry Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials 2013.